The Guardian view on Merck’s exit: Britain’s biopharma technique stalls within the face of China’s rise | Editorial

When Merck abruptly scrapped its billion-pound London analysis hub final week, critics blamed Britain’s lacklustre help for all times sciences and a Scrooge-like grip on NHS drug costs. However one vital issue might have been missed. That Merck, which can be reducing jobs elsewhere – 6,000 globally – is recalibrating not simply in response to the UK or the US, however to China.